Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.02 and traded as high as $2.00. Cortexyme shares last traded at $1.85, with a volume of 168,423 shares.
Cortexyme Price Performance
The stock has a market cap of $53.67 million, a P/E ratio of -0.60 and a beta of 1.40. The stock’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.03.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- What is Short Interest? How to Use It
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What Are Dividend Achievers? An Introduction
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- What Are Dividend Champions? How to Invest in the Champions
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
